- Home
- EBMT vs FATE Comparison
EBMT vs FATE Comparison
Compare EBMT & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | FATE |
|---|---|---|
| Founded | 1922 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 124.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | EBMT | FATE |
|---|---|---|
| Price | $20.55 | $1.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 35.1K | ★ 1.8M |
| Earning Date | 01-22-2026 | 03-04-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | ★ 58.15 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $87,531,000.00 | $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $12.21 | ★ N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $14.70 | $0.66 |
| 52 Week High | $21.18 | $1.94 |
Technical Indicators
Market Signals| Indicator | EBMT | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 58.53 | 59.63 |
| Support Level | $20.09 | $1.02 |
| Resistance Level | $21.18 | $1.32 |
| Average True Range (ATR) | 0.55 | 0.08 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 60.43 | 69.86 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.